Evaluating inobrodib (CCS1477) in combination with teclistamab or elranatamab in patients with relapsed/refractory multiple myeloma; specific cohorts within a phase I/IIa study evaluating inobrodib in patients with advanced hematological malignancies
Searle, E. Knurowski, T. Gooding, S. Campbell, V. Moore, S. Chaidos, A. Travers, J. Creasey, T. Clegg, K. Somervaille, T.
Searle, E.
Knurowski, T.
Gooding, S.
Campbell, V.
Moore, S.
Chaidos, A.
Travers, J.
Creasey, T.
Clegg, K.
Somervaille, T.
Abstract
Description
Date
2025
Publisher
Collections
Keywords
Type
Article
Citation
Searle E, Knurowski T, Gooding S, Campbell V, Moore S, Chaidos A, et al. Evaluating inobrodib (CCS1477) in combination with teclistamab or elranatamab in patients with Relapsed/Refractory multiple myeloma; specific cohorts within a phase I/IIa study evaluating inobrodib in patients with advanced hematological malignancies. Blood. 2025 NOV 3;146:8242-.